air/oxygen
Phase 3Small molecule
air/oxygen is one of 78 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
557 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Veramyst
GSKPreclinical
air/oxygen
TTurku University Hospital
Phase 3
Flovent
GSKPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Narcan
SScienture
Preclinical
Coumadin
AAbbott
Preclinical
Zoloft
VViatris Specialty LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for air/oxygen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTurku University Hospital